The drug and vaccine landscape for neglected diseases (2000–11): a systematic assessment

by Dr. Belen Pedrique, MD, Nathalie Strub-Wourgaft, MD, Claudette Some, PharmD, Piero Olliaro, MD, Patrice Trouiller, PharmD, Nathan Ford, PhD, Bernard Pécoul, MD, Jean-Hervé Bradol, MD
Published 2013-12-01

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

by Victor Kande Betu Ku Mesu, DPH, Wilfried Mutombo Kalonji, MD, Clélia Bardonneau, MSc, Olaf Valverde Mordt, MSc, Digas Ngolo Tete, MPH, Séverine Blesson, MSc, François Simon, MSc, Sophie Delhomme, MSc, Sonja Bernhard, PhD, Hélène Mahenzi Mbembo, MD, Christian Mpia Moke, MD, Steven Lumeya Vuvu, MMed, Junior Mudji E'kitiak, MD, Felix Akwaso Masa, MD, Melchias Mukendi Ilunga, MD, Dieudonné Mpoyi Muamba Nzambi, MD, Tim Mayala Malu, MD, Serge Kapongo Tshilumbwa, MD, Franck Botalema Bolengi, MD, Mathieu Nkieri Matsho, MD, Crispin Lumbala, MPH, Bruno Scherrer, PhD, Nathalie Strub-Wourgaft, MD, Antoine Tarral, MD
Published 2021-07-01